PMS-DEXTROAMPHETAMINE DIN 02447673
Health Canada record
| Active ingredient(s) | DEXTROAMPHETAMINE SULFATE 5 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | CONTROLLED DRUGS (CDSA I) |
| Class | Human |
| ATC | N06BA02 DEXAMFETAMINE |
| Original market date | |
| Current status date | 09-Apr-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pharmascience Inc. — licence 100241, currently licensed, last inspection rating C (2025-03-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DEXTROAMPHETAMINE SULFATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02481464 | APO-DEXTROAMPHETAMINE SR | APOTEX INC | Capsule (Sustained-Release) | DEXTROAMPHETAMINE SULFATE 10 MG | Approved |
| 02481472 | APO-DEXTROAMPHETAMINE SR | APOTEX INC | Capsule (Sustained-Release) | DEXTROAMPHETAMINE SULFATE 15 MG | Approved |
| 01924516 | DEXEDRINE | KNIGHT THERAPEUTICS INC. | Tablet | DEXTROAMPHETAMINE SULFATE 5 MG | Marketed |
| 01924559 | DEXEDRINE SPANSULE | KNIGHT THERAPEUTICS INC. | Capsule (Sustained-Release) | DEXTROAMPHETAMINE SULFATE 10 MG | Marketed |
| 01924567 | DEXEDRINE SPANSULE | KNIGHT THERAPEUTICS INC. | Capsule (Sustained-Release) | DEXTROAMPHETAMINE SULFATE 15 MG | Marketed |
| 02443236 | DEXTROAMPHETAMINE | AA PHARMA INC | Tablet | DEXTROAMPHETAMINE SULFATE 5 MG | Marketed |
| 02566605 | PMS-DEXTROAMPHETAMINE | PHARMASCIENCE INC | Tablet | DEXTROAMPHETAMINE SULFATE 5 MG | Approved |
| 02448327 | TEVA-DEXTROAMPHETAMINE SR | TEVA CANADA LIMITED | Capsule (Sustained-Release) | DEXTROAMPHETAMINE SULFATE 15 MG | Marketed |
| 02448319 | TEVA-DEXTROAMPHETAMINE SR | TEVA CANADA LIMITED | Capsule (Sustained-Release) | DEXTROAMPHETAMINE SULFATE 10 MG | Marketed |
International API supply for DEXTROAMPHETAMINE SULFATE
8 active FDA Drug Master Files.
Request a quote for PMS-DEXTROAMPHETAMINE